Application routes for Zhujian Powder Veterinary Grade API are downstream pharmaceutical manufacturing operations rather than chemical end-uses. The powder is received as an active pharmaceutical ingredient, and the batch documentation for assay, related substances, residual solvents, water content, particle-size distribution, and microbial limits controls every downstream decision. Different dosage forms pull different physical properties to the front of the process: injectable solutions stress solubility and filterability; tablet compression stresses flow and compactability; capsule filling stresses static charge and bed uniformity; drinking-water powders stress dispersion and sedimentation; medicated premixes stress carrier adhesion and low-inclusion homogeneity; lyophilised injection stresses glass transition and reconstitution. In each route the formulation addition ratio is calculated from the labelled dose, batch size, assay as-is or dried-basis assay, and water correction, not transferred from a fixed generic recipe.

Sterile Injectable Solutions: Terminal Sterilisation Versus Aseptic Filling Boundaries

Sterile injectable solution manufacture receives the powder API as a dissolution input. Water for Injection is charged at 60–80% of final batch volume into a jacketed stainless steel vessel at 20–25 °C unless solubility data force a temperature rise to 45 °C; the API is added under agitation at 200–400 rpm. The addition ratio is set from the registered label claim and is expressed as concentration, typically 0.1% w/v to 25.0% w/v depending on dose and solubility. The corrected powder input is not the same as the label claim because the certificate of analysis reports dried-basis assay and water content. For a 100 mg/mL solution, with 98.0% dried-basis assay and 0.5% water, the corrected powder input is 102.6 mg per millilitre. The powder is dissolved first, pH is adjusted with 0.1 M hydrochloric acid or sodium hydroxide, and the solution is brought to final volume with Water for Injection. If the active is oxygen-sensitive, nitrogen overlay is maintained from the dissolution step through filling.

Compliance for sterile veterinary injectables is anchored to EU GMP Annex 1, 21 CFR 211.113(b) for sterilising filtration validation, and Ph. Eur. 5.1.1 for methods of preparation of sterile products. Finished-product sterility is tested by Ph. Eur. 2.6.1; bacterial endotoxins by Ph. Eur. 2.6.14; sub-visible particulate matter by Ph. Eur. 2.9.19. The endotoxin limit is derived from the registered maximum dose, not a universal fixed limit. Vial and stopper quality is governed by the relevant Ph. Eur. 3.2 container chapters, and the filtration train is validated with the specific product because API concentration, pH, and preservative can shift filter pore-wetting behaviour. The production process then follows a sterilising filtration step through a 0.45 µm prefilter and a validated 0.22 µm polyethersulfone or polyvinylidene fluoride membrane. Where thermostability allows, terminal sterilisation at 121 °C for 15 min is preferred over aseptic filtration because it achieves a higher sterility assurance level. Vials are depyrogenated at 250 °C for 45 min; stoppers are washed and steam-sterilised. Filling is performed under ISO 14644-1 ISO 5 unidirectional airflow with rotary-piston or peristaltic pumps. In-process fill weight is monitored gravimetrically, and filter integrity is tested before and after the filling campaign. Terminal finished-product types include single-dose vials, multi-dose vials containing a preservative, ampoules, and pre-filled syringes for companion-animal parenteral delivery.

The main operational boundary is moisture and solubility. If the powder is hygroscopic, open handling is limited to ≤ 30% relative humidity and ≤ 4 h, and the dissolution vessel must be closed after each addition. The formulation should not be combined with phosphate buffers if the API forms low-solubility phosphate salts; filter compatibility with polyethersulfone and polyvinylidene fluoride must be verified before scale-up because API precipitation on the membrane can reduce throughput below the validated minimum bubble point.

What Restricts Direct Compression of This API in Veterinary Tablet Cores?

In tablet core manufacture, direct compression is restricted less by the biological potency of the API than by the flow and compaction behaviour that emerges when the active exceeds approximately 20–25% w/w of the core. On production rotary presses equipped with B-tooling, a high-elastic-recovery API can produce capping, lamination, and edge-chipping when the punch speed exceeds 30 rpm and compaction force is forced above 8 kN. The development route therefore begins with powder-flow measurement under USP General Chapter 1174 and Ph. Eur. 2.9.36, followed by compression profiles on an instrumented single-punch press before transfer to a 12- or 16-station rotary press. Batch documents record the API addition ratio as a weight fraction of the core: for a 250 mg tablet carrying 25 mg of active, the API ratio is 10.0% w/w. Low-dose tablets at 5 mg per tablet are prepared through a 1:10 lactose trituration and may contain final API ratios as low as 0.5% w/w. A high-dose 100 mg active in a 400 mg core corresponds to 25.0% w/w, above which dry granulation by roller compaction is typically introduced. Magnesium stearate is held to 0.25–1.0% w/w, and the post-lubricant blending time is limited to 3–5 min to avoid excessive coating of disintegrant and dissolution slowdown.

Compliance for non-sterile veterinary tablets is anchored to 21 CFR 211.110, 21 CFR 211.67, and 21 CFR 211.165, with release testing under USP General Chapter 905 for uniformity of dosage units, USP General Chapter 701 for disintegration when required, USP General Chapter 711 for dissolution, and USP General Chapter 1216 for friability. Elemental impurities are assessed against ICH Q3D, and residual solvents against ICH Q3C. The downstream blending operation screens the API through a 600 µm sieve and blends it with microcrystalline cellulose, lactose monohydrate or dibasic calcium phosphate, crospovidone or sodium starch glycolate, and colloidal silicon dioxide before lubrication. Tablets are compressed on a rotary tablet press with force-feeder control; tablet hardness, thickness, weight uniformity, and friability are monitored at defined intervals. If the API or blend water content exceeds 3.0% w/w, wet bridging in the feed frame can produce weight variation above 2.0% RSD; therefore the compression suite is held at ≤ 30% RH for moisture-sensitive batches. Terminal formats include uncoated tablets, film-coated tablets, scored tablets for partial dosing, and chewable tablets for canine or feline administration.

Hard capsule filling with the powder API becomes the preferred route when batch size is under approximately 50 kg or when the active substance shows compaction-pressure sensitivity that cannot be managed by wet granulation. The powder is delumped through a 600 µm sieve and milled when certificate-of-analysis particles exceed 180 µm, because oversize active particles create weight variation during dosator or tamping-pin filling. The fill blend contains lactose monohydrate or mannitol as the main diluent; colloidal silicon dioxide is added at 0.5–2.0% w/w to reduce static charge, and crospovidone or sodium starch glycolate functions as the internal disintegrant. For a size 0 capsule with a target fill weight between 350 mg and 450 mg, the API addition ratio typically ranges from 5.0% w/w to 60.0% w/w depending on labelled dose. Low-dose products at 1 mg per capsule require a lactose trituration because direct weighing of the active would fall below the repeatability limit of the dispensing balance. Capsule production is controlled under 21 CFR 211.101 for charge-in and 21 CFR 211.110 for in-process control; empty shell quality is checked against the Ph. Eur. capsules monograph, and TSE risk for gelatin is documented under Ph. Eur. 5.2.8. Finished capsules are tested for uniformity of dosage units by USP General Chapter 905, disintegration by USP General Chapter 701, and microbial quality by Ph. Eur. 2.6.12 and Ph. Eur. 2.6.13.

The downstream filling operation uses an intermittent motion capsule machine with dosator or tamping-pin stations. At speeds above 60,000 capsules/h, powder bed height in the hopper must be maintained within a narrow band because bed pressure shifts fill weight by up to 2%. Filled capsules pass through checkweighers and metal detectors; empty-shell separation is weight-based rather than visual. Terminal formats include hard gelatin capsules and hydroxypropyl methylcellulose capsules for companion-animal products requiring non-gelatin shell claims. The operational boundary is static electricity: below 20% RH, the API powder may adhere to capsule body and cap surfaces, causing splitting and dust generation. The filling suite is therefore maintained at 30–40% RH, and the blend must not contain water-miscible binders that soften the shell at the filling contact points.

Where poultry, swine, or calves require mass medication through drinking water, the powder API is converted into a dispersible oral powder or granule rather than a compacted solid. The decisive powder property is particle size after milling, not the as-received particle size. Material that remains above 200 µm will sediment in header tanks and produce inhomogeneous exposure; the powder is therefore air-jet milled or pin milled to a d90 below 75 µm. The bulk formulation uses water-soluble carriers such as lactose, sucrose, or a buffered citrate/carbonate system; the buffering system prevents pH drift below 6.0 in hard water, which can depress the solubility of weak acid actives and clog nipple drinkers. The API addition ratio is expressed in medicated water rather than bulk percentage: a product containing 100 g of API per kg, dosed at 0.5 g product per litre, delivers 50 mg of API per litre. This rate is adjusted from flock water intake, body weight, and the prescribed dose; published data for this specific powder grade’s dispersibility in hard water is limited, and a stability-dispersibility study in the target water quality is required before registration.

Regulatory compliance for drinking-water veterinary products follows EU Regulation 2019/6 for veterinary medicinal products and, in the United States, the applicable new animal drug conditions under 21 CFR Part 514. Powder fineness is controlled by USP General Chapter 811 or Ph. Eur. 2.9.35; delivered dose uniformity after reconstitution is evaluated by Ph. Eur. 2.9.40 with the maximum tolerated variation stated in the marketing authorisation. The downstream process blends the milled API with carriers in a double-cone or V-blender, then fills the blend into laminated aluminium foil sachets at ≤ 30% RH with heat-sealed closures. Seal strength is verified by ASTM F88, and bulk pails receive a desiccant sachet when the powder is hygroscopic. Terminal products include 1 g/10 g sachets, multi-dose pails, and calibrated scoop packs for farm use. The principal process conflict is residual moisture: above 2.5% w/w water, lactose-based powders cake in storage and fail sieve re-dispersion tests. Granulation is reserved for dust-controlled products; fluid-bed granulation with a binder solution at 2–5% w/w solids is used, but the granules must dissolve or disperse within 3 min in water at 15 °C to avoid blocking automatic proportioning pumps.

When the API Is Diluted Into a Medicated Premix, Carryover Becomes the Release Criterion

Medicated feed premix production begins with carrier selection, not with API particle-size reduction. The API powder is adhered to a carrier such as rice hulls, corn cob fractions, or calcium carbonate with a particle size between 200 µm and 500 µm. Carrier moisture is held below 12.0% w/w to prevent mould growth and API degradation; mineral oil may be sprayed at 0.5–1.5% w/w to bind fine API particles to the carrier surface. The API addition ratio is calculated from the target dose and feed intake: g API per tonne = (mg API per kg body weight × kg body weight × number of animals) ÷ kg feed consumed. As a registered premix concentration, the API content can range from 1 g/kg to 100 g/kg, and the premix is then incorporated into final feed at 0.5–5 kg per metric tonne. The critical release criterion is not mean assay alone but blend homogeneity; after mixing, ten samples drawn from different mixer positions must show a coefficient of variation below 5.0%.

Compliance is anchored to 21 CFR Part 225 for current good manufacturing practice in medicated feed production and, where applicable, EU Regulation 2019/4 on medicated feed manufacture and carryover prevention. Type A medicated article controls in the United States are established under 21 CFR Part 226. Mixing is carried out in a ribbon blender or paddle mixer; the API is introduced in a stepwise geometric dilution rather than as a single charge. The premix is blended for 10–20 min after active addition, and batch size should not exceed 80% of mixer working volume because overfilled mixers create dead zones at the shaft ends. Discharge is through an automated valve into bags or bulk totes; dust extraction at the discharge point must be validated to prevent API carryover into subsequent non-medicated batches. Terminal formats include medicated premix bags, bulk totes for integrated feed mills, and mineral block premixes where the carrier binder supports compression into blocks.

Production lines must be dedicated or validated for cleaning because low-level carryover of this veterinary API into feed for non-approved species can create residue violations. When the registered API belongs to a class with species-specific toxicity, such as ionophore anticoccidials in horses, separate production and storage are mandatory. For non-ionophore actives, the site still applies hazard analysis under ISO 22000 or HACCP. Sequenced campaigns from low-dose to high-dose and direct-swab assay verification before line release are required. The premix must not be blended into liquid feed supplements without a stability study, because some carriers separate in high-moisture liquid systems and the API may settle below the labelled concentration in the tank.

Lyophilised Plug Formation and Reconstitution Limits

For veterinary active powders that require a sterile dry presentation, freeze-drying converts the dissolved API into a porous plug for reconstitution; the dry powder itself is not directly lyophilised. The API is first dissolved or suspended at the target reconstitution concentration, commonly 50 mg/mL to 200 mg/mL, with mannitol or glycine added at 2–5% w/v to provide cake structure and collapse-temperature stability. The API addition ratio is therefore expressed as API per vial: a 500 mg vial filled at 100 mg/mL requires a fill volume of 5.0 mL. The solution is sterile-filtered through a 0.22 µm membrane and filled into Type I glass vials, partially stoppered, and loaded onto shelves pre-cooled to 5 °C. Freezing is performed at -40 °C to -50 °C for 2–4 h; primary drying is run at shelf temperatures between -20 °C and 0 °C with chamber pressure at 0.2 mbar to 0.4 mbar; secondary drying raises shelf temperature to 25–35 °C for 4–6 h until Karl Fischer moisture is not more than 1.0% w/w.

Compliance for lyophilised veterinary injections is governed by EU GMP Annex 1, 21 CFR 211.113, Ph. Eur. 2.6.1, and Ph. Eur. 2.6.14. Container closure integrity is verified by dye ingress, vacuum decay, or helium leak under USP General Chapter 1207, and rubber closure quality is assessed by the Ph. Eur. 3.2.9 monograph for closures for freeze-dried products. The finished lyophilised product is tested for reconstitution time, which should be below 2 min in the specified diluent, and for absence of visible aggregates after reconstitution. Terminal formats include single-dose lyophilised vials, dual-chamber syringes where the diluent is stored separately, and companion-animal multi-dose vials if preservative compatibility is demonstrated.

The main operational boundary is collapse temperature: if the primary drying shelf temperature exceeds the collapse temperature of the formulation by more than 2–3 °C, the plug loses mechanical integrity and the product fails reconstitution time. A hydrophobic API may require a lyoprotectant and co-solvent; however, co-solvents such as tert-butanol must be controlled under ICH Q3C residual solvent limits. The product is backfilled with nitrogen to 800 mbar before stoppering to protect oxygen-sensitive actives. Lyophilisation should not be used as a substitute for solubility improvement; if the API is not fully dissolved before filtration, the filter retention test will fail and the cake will contain non-uniform active distribution.